Abstract
At the 2012 ASH meeting the topic “AML” was presented in the Ham–Wassermann lecture, an excellent educational symposium with numerous oral and poster presentations. Recent progress in the field of cytotoxic chemotherapy seems rather slow, but significant improvement in the understanding of the pathogenesis of acute myeloid leukemia (AML) has led to the identification of recurrent gene mutations; some of them already have changed treatment strategies in specific patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lo-Coco F, Avvisati G, et al. ATRA and arsenic trioxide (ATO) versus ATRA and idarubicin (AIDA) for newly diagnosed, non high-risk acute promyelocytic leukemia (APL): results of the phase III, prospective, randomized Intergroup APL0406 study by the Italian-German Cooperative Groups GIMEMA-SAL-AMLSG. Blood (ASH annual meeting abstracts). 2012;120:6
Röllig C, et al. Sorafenib versus placebo in addition to standard therapy in adult patients ³ 60 years with newly diagnosed acute myeloid leukemia: results from the randomized-controlled Soraml trial. Blood. (ASH annual meeting abstracts). 2012;120:144
Cortez JE, et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients ³ 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Blood. (ASH annual meeting abstracts). 2012;120:48
Smith CS, et al. Crenolanib (CP-868,596) is a potent and selective type I FLT3 inhibitor that retains activity against AC220 resistance causing FLT3 kinase domain mutants. Blood. (ASH annual meeting abstracts). 2012;120:141
Burnett AK, et al. A comparison of daunorubicin/ARA-C (DA) Versus daunorubicin/clofarabine (DClo) and two versus three courses of total treatment for older patients with AML and high risk MDS: results of the UK NCRI AML16 Trial. Blood. (ASH Annual Meeting Abstracts). Nov 2012;120:892
Schlenk RF, et al. Azacitidine-containing regimens followed by azacitidine maintenance therapy in high risk acute myeloid leukemia: first results of the randomized phase-II AMLSG 12-09 study (Clinical trials.gov no. NCT01180322). Blood. (ASH annual meeting abstracts). 2012;120:412
Blum W, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia (AML) in first remission: a phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance). Blood. (ASH Annual Meeting Abstracts). Nov 2012;120:44
Patel JP, Levine RL. How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia? Hematology. 2012;2012:28–34. doi:10.1182/asheducation-2012.1.28
Conflict of interest
The authors declare that there is no actual or potential conflict of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koller, E. Acute myeloid leukemia: highlights from the 54th ASH meeting held in Atlanta, Georgia. memo 6, 185–188 (2013). https://doi.org/10.1007/s12254-013-0101-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-013-0101-0